An observational study in PHACE Syndrome and Infantile Hemangioma (IH), sponsored by West China Hospital. Recruiting at 3 sites in China. Open to participants aged 0 Months to 12 Months. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by West China Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Hemangioma, Capillary with a site in China — 6 open to participants now, 7 under way, 1 of them phase 3. Hemangioma, Capillary · China.
Among the 12 studies in Hemangioma, Capillary with a site in China, this one is the only one that started in 2022, is one of 7 observational ones, and was the 11th registered.
35 studies on the registry are indexed under Hemangioma, Capillary; 6 are open to participants now.
Browse Hemangioma, Capillary studies →6 of the 12 studies in Hemangioma, Capillary with a site in China are open now. Recruiting first, the newest first:
West China Hospital · Sites in China
Ages 0 days–7 days · Healthy volunteers
West China Hospital · Sites in China
Ages up to 6
West China Hospital · Sites in China
Ages 6 mo–60 mo
West China Hospital · Sites in China
Ages 0 mo–12 mo
West China Hospital · Sites in China
Ages 0–10
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 3 Hemangioma, Capillary studies recruiting now, none set no upper age limit and 3 stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.
This study: 0 Months to 12 Months · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 3 · Phase 4 1
First in 2013; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 3 is below the median of 150 across 14 observational studies indexed under Hemangioma, Capillary.
Median enrollment 168 across the 5 interventional studies, 150 across the 7 observational. Of the 3 that completed or were terminated, 1 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 12 have an industry lead sponsor. The 5 most frequent:
West China Hospital is the lead sponsor of 503 studies on the registry; 247 are open to participants now.
West China Hospital has 8 studies filed under Hemangioma, Capillary — fewer than ten, so there is no comparison to draw.
3 of the studies in Hemangioma, Capillary with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07938710West China HospitalIncidence and Clinical Features of PHACE Syndrome | 2027-03-31 |
| NCT07616323West China HospitalScreening LUMBAR Syndrome in Infants With Infantile Hemangiomas | 2027-06-30 |
| NCT07938723West China HospitalThe Incidence and Clinical Characteristics of Infantile Hemangiomas | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 12 studies in Hemangioma, Capillary with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will include infants seen at three hospitals who have a segmental infantile hemangioma, a blood vessel growth affecting a broad area of skin. Eligible areas include the scalp, face, neck, upper chest or back, and shoulder or upper arm. The study will measure how often PHACE syndrome is found in infants with enough clinical information to determine the diagnosis. PHACE syndrome can involve differences in the development of the brain, arteries, heart, eyes, or the midline of the chest and abdomen. The study team will describe these findings and the hemangiomas. The treating clinicians will manage evaluation and care.
This prospective observational cohort will consecutively invite infants with a clinician-confirmed segmental cutaneous infantile hemangioma involving the head (including the scalp and face), neck, upper trunk, or proximal upper extremity at their first qualifying presentation to a participating center. Infants can enroll regardless of whether a PHACE evaluation or diagnosis is already documented. Prior evaluation and referral source will be recorded. Each infant will be enrolled once. A parent or legal guardian will provide written informed consent.
At enrollment, study clinicians will record age, sex, the anatomic distribution and laterality of the segmental lesions, the longest diameter of the largest qualifying lesion, and lesion depth. Photographs will be recorded when permitted by the protocol and consent. Each infant will be assigned to one anatomic stratum. The strata are head involvement with or without other sites, isolated neck, isolated upper trunk, isolated proximal upper extremity, and multiple sites without head involvement. All involved regions will also be recorded.
The study will collect clinical findings and results of clinically indicated assessments, including examination for ocular and ventral midline abnormalities, echocardiography, and magnetic resonance imaging and angiography of the head and neck, with aortic arch assessment. The treating team will determine which examinations and treatments are clinically appropriate. Prior assessments can contribute to classification when they meet the same protocol criteria for adequacy.
A central panel will apply the revised 2016 PHACE consensus diagnostic criteria. A hemangioma of the head, including the scalp, that exceeds 5 cm in diameter supports a diagnosis of definite PHACE when accompanied by at least one major or two minor criteria. For large segmental hemangiomas of the neck, upper trunk, or trunk with proximal upper-extremity involvement, definite PHACE requires at least two major criteria. Isolated proximal upper-extremity lesions will be described separately. Classification as definite PHACE will require documented fulfillment of the consensus criteria.
The primary analysis will include infants with a protocol-defined evaluable assessment by six months after enrollment. An evaluable assessment requires interpretable documentation of the prespecified core clinical, cardiac, and neurovascular evaluations, irrespective of the diagnostic classification. Definite PHACE, possible PHACE, and neither category will be reported separately. Inadequate evaluations will be recorded with the reason and retained in the enrollment count. The study will report the assessment completion proportion and the definite PHACE proportion with 95% confidence intervals overall and by anatomic stratum where estimable.
Infants from birth through 12 months of age at their first qualifying presentation during the recruitment period at one of the three participating centers, with a segmental cutaneous infantile hemangioma involving the head (including the scalp and face), neck, upper trunk, or proximal upper extremity.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Infants with a segmental cutaneous infantile hemangioma involving the head (including the scalp and face), neck, upper trunk, or proximal upper extremity who are enrolled at one of the three participating centers.
Proportion of Evaluable Infants With PHACE Syndrome
Percentage of infants with an evaluable PHACE assessment who fulfill the revised 2016 consensus criteria for PHACE. Evaluable assessments have the prespecified core clinical, cardiac, and neurovascular evaluations documented and interpretable. Each infant is counted once.
Time frame: At enrollment through 6 months after enrollment.
Anatomic Distribution and Laterality of Segmental Hemangiomas
Number and percentage of infants by involved anatomic region and lesion laterality (left, right, bilateral, or midline) among infants with evaluable lesion documentation.
Time frame: At enrollment.
Plan to share: Undecided
Started Apr 2022 (actual). Primary completion is estimated for Mar 2027, 59 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.